Table 2.
ORRs for patients receiving dostarlimab + chemotherapy and pembrolizumab + chemotherapy (ITT population as of July 7, 2023)
| Dostarlimab + chemotherapy (N = 121) | Pembrolizumab + chemotherapy (N = 122) | |
|---|---|---|
| Best overall response, n (%) | ||
| Complete response | 4 (3) | 6 (5) |
| Partial response | 51 (42) | 42 (34) |
| Stable disease | 49 (40) | 48 (39) |
| Progressive disease | 12 (10) | 12 (10) |
| Not evaluable | 0 | 1 (<1) |
| Not donea | 5 (4) | 13 (11) |
| ORR, n (%) | ||
|
Complete response + partial response 95% CI |
55 (45) 36.4–54.8 |
48 (39) 30.6– 48.6 |
| ORR by PD-L1 TPS subgroup, n/N (%) | ||
|
TPS < 1% 95% CI |
13/50 (26) 15–40 |
20/51 (39) 26–54 |
|
TPS ≥ 1% 95% CI |
42/71 (59) 47–71 |
28/71 (39) 28–52 |
|
TPS 1–49% 95% CI |
22/44 (50) 35–65 |
15/44 (34) 21–50 |
|
TPS ≥ 50% 95% CI |
20/27 (74) 54–89 |
13/27 (48) 29–68 |
ORR was assessed per RECIST v1.1 based on BICR.
BICR blinded independent central review, CI confidence interval, ITT intention-to-treat, ORR overall response rate, PD-L1 programmed death ligand-1, RECIST v1.1 Response Evaluation Criteria in Solid Tumors version 1.1, TPS tumor proportion score.
aPatients with ORR listed as ‘not done’ had unknown or missing responses. The reasons for unknown or missing responses in each arm are listed in Supplementary Table 4.